{'52WeekChange': 0.12224114,
 'SandP52WeekChange': None,
 'address1': '1220 Concord Avenue',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 6.69,
 'askSize': 3200,
 'averageDailyVolume10Day': 1476887,
 'averageVolume': 2046214,
 'averageVolume10days': 1476887,
 'beta': 1.289635,
 'beta3Year': None,
 'bid': 6.52,
 'bidSize': 2200,
 'bookValue': 0.686,
 'category': None,
 'circulatingSupply': None,
 'city': 'Concord',
 'companyOfficers': [],
 'country': 'United States',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 6.71,
 'dayLow': 6.38,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': -16.122,
 'enterpriseToRevenue': 13.371,
 'enterpriseValue': 1012898240,
 'exDividendDate': None,
 'exchange': 'NMS',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fiftyDayAverage': 6.556857,
 'fiftyTwoWeekHigh': 7.49,
 'fiftyTwoWeekLow': 2.71,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 148471279,
 'forwardEps': -0.35,
 'forwardPE': -18.685715,
 'fromCurrency': None,
 'fullTimeEmployees': 254,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'headSymbol': None,
 'heldPercentInsiders': 0.02118,
 'heldPercentInstitutions': 0.66098,
 'industry': 'Biotechnology',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': None,
 'lastSplitFactor': None,
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/cerus.com',
 'longBusinessSummary': 'Cerus Corporation, a biomedical products company, '
                        'focuses on developing and commercializing the '
                        'INTERCEPT Blood System to enhance blood safety. Its '
                        'INTERCEPT Blood System, a proprietary technology for '
                        'controlling biological replication is designed to '
                        'reduce blood-borne pathogens in donated blood '
                        'components intended for transfusion. The company '
                        'offers INTERCEPT Blood Systems for platelets and '
                        'plasma that is designed to inactivate blood-borne '
                        'pathogens in platelets and plasma donated for '
                        'transfusion; and INTERCEPT Blood System for red blood '
                        'cells to inactivate blood-borne pathogens in red '
                        'blood cells donated for transfusion. It sells '
                        'platelet and plasma systems through its direct sales '
                        'force and distributors in the United States, Europe, '
                        'the Commonwealth of Independent States, the Middle '
                        'East, Latin America, and internationally. The company '
                        'has a collaboration with the National Trauma '
                        'Institute to supply Intercept plasma for use in the '
                        'plasma resuscitation without lung injury (PROpOLIs) '
                        'clinical study. Cerus Corporation was founded in 1991 '
                        'and is headquartered in Concord, California.',
 'longName': 'Cerus Corporation',
 'market': 'us_market',
 'marketCap': 1072481536,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_26334',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1585612800,
 'navPrice': None,
 'netIncomeToCommon': -68918000,
 'nextFiscalYearEnd': 1640908800,
 'open': 6.52,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': None,
 'phone': '925-288-6000',
 'previousClose': 6.61,
 'priceHint': 2,
 'priceToBook': 9.533527,
 'priceToSalesTrailing12Months': 14.157051,
 'profitMargins': -0.90974,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 6.71,
 'regularMarketDayLow': 6.38,
 'regularMarketOpen': 6.52,
 'regularMarketPreviousClose': 6.61,
 'regularMarketPrice': 6.52,
 'regularMarketVolume': 1420506,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 163988000,
 'sharesPercentSharesOut': 0.064,
 'sharesShort': 10488906,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 8266451,
 'shortName': 'Cerus Corporation',
 'shortPercentOfFloat': 0.0654,
 'shortRatio': 4.5,
 'startDate': None,
 'state': 'CA',
 'strikePrice': None,
 'symbol': 'CERS',
 'threeYearAverageReturn': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': -0.476,
 'twoHundredDayAverage': 5.3549643,
 'underlyingExchangeSymbol': None,
 'underlyingSymbol': None,
 'uuid': '986b70aa-e85d-3fdd-978b-d29090a8b43b',
 'volume': 1420506,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://www.cerus.com',
 'yield': None,
 'ytdReturn': None,
 'zip': '94520'}